最后手段的药物：多黏菌素耐药性的最新进展。
Agents of Last Resort: An Update on Polymyxin Resistance.
机构信息
Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, No.9 Dongdan Santiao, Dongcheng District, Beijing, China.
Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church Street, Ann Arbor, MI 48109, USA.
出版信息
Infect Dis Clin North Am. 2020 Dec;34(4):723-750. doi: 10.1016/j.idc.2020.08.003. Epub 2020 Sep 30.
Polymyxin resistance is a major public health threat, because the polymyxins represent last-line therapeutics for gram-negative pathogens resistant to essentially all other antibiotics. Minimizing any potential emergence and dissemination of polymyxin resistance relies on an improved understanding of mechanisms of and risk factors for polymyxin resistance, infection prevention and stewardship strategies, together with optimization of dosing of polymyxins (eg, combination regimens).
多粘菌素耐药性是一个主要的公共卫生威胁，因为多粘菌素是对基本上所有其他抗生素耐药的革兰氏阴性病原体的最后一线治疗药物。为了最大限度地减少多粘菌素耐药性的任何潜在出现和传播，需要更好地了解多粘菌素耐药性的机制和危险因素、感染预防和管理策略，以及优化多粘菌素的剂量（例如，联合治疗方案）。
Zotero 插件